Understanding current events through the lenses of the past and future.
Wall Street Journal
https://www.wsj.com/articles/pepperand-salt-9dba1f63
Merck is close to a $1.3 billion deal to buy Eyebiotech, whose lead drug, Restoret, is in development to treat eye conditions including a form of age-related macular degeneration.
Former Trump official wins tight Texas GOP primary runoff
